<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260528069554N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-06-03</date_registration>
      <primary_sponsor>Fatima Memorial Hospital Lahore</primary_sponsor>
      <public_title>Can Ropivacaine Help Reduce Pain After Perianal Procedures?</public_title>
      <acronym></acronym>
      <scientific_title>Role of Ropivacaine Infiltration in Postoperative Analgesia for Perianal Procedures: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/90443</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group using permuted block randomization with a fixed block size of eight. A computer-generated randomization sequence will be prepared by an investigator who is not involved in patient recruitment or outcome assessment. The allocation sequence will be placed in sequentially numbered, opaque, sealed envelopes. After obtaining informed consent and confirming eligibility, the recruiting investigator will open the next envelope in numerical order to determine the participant's group assignment. This process will ensure both random allocation and allocation concealment until the time of assignment, Blinding description: There is double blinding. Both the participants and the investigator involved will be blinded to treatment allocation. Participants randomized to the intervention group will receive ropivacaine injection, while those in the control group will receive 20 mL of normal saline placebo. The solutions will be prepared in identical syringes containing equal volumes, making them indistinguishable in appearance. An independent individual not involved in participant enrollment, intervention administration, outcome assessment, or data analysis will prepare the solutions.</study_design>
      <phase>4</phase>
      <hc_freetext>Condition 1: Peri-Anal Surgical Conditions-( Fistula in ANO + Chronic Anal Fissure). Condition 2: Peri-Anal Surgical Conditions( Haemorrhoids).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: International Non-proprietary Name (INN):Ropivacaine                                         Dose: 20 mL of 0.25% ropivacaine infiltration administered once at the end of surgery                              Duration of Treatment: Single intraoperative administration with postoperative assessment over 24hr                                                                                                                                                                   Mode of Delivery: Local surgical site infiltration (perianal wound infiltration). Intervention 2: Control group: International Non-proprietary Name (INN):Normal Saline                                              Dose: 20 mL of 0.9% Normal Saline infiltration administered once at the end of surgery                  Duration of Treatment: Single intraoperative administration with postoperative assessment over 24hr                 Mode of Delivery: Local surgical site infiltration (perianal wound infiltration).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data:
• Published results
• Primary outcome

When:
From:
After publication of main results
To:
No end date

To whom:
1)Anyone
2)Researchers

Conditions:
1)Systematic reviews and meta-analyses
2)Health economic analyses
3)Studies testing whether findings can be repeated or confirmed
4)Teaching research methods or developing new statistical techniques

Where to obtain:
Email of trial custodian, sponsor or committee: rana.jee789@gmail.com

How to obtain:
Requires approval by an ethics committee
Requires a data sharing agreement between data requester and trial custodian or sponsor

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abdullah Ayub</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Agro Flats Shadman-1 Lahore.</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 316 7135772</telephone>
        <email>rana.jee789@gmail.com</email>
        <affiliation>Fatima Memorial Hospital Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abdullah Ayub</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Agro flats, Shadman-1 Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 316 7135772</telephone>
        <email>rana.jee789@gmail.com</email>
        <affiliation>Fatima Memorial Hospital Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>• Patients aged 20–60 years
• Either gender
• Patients undergoing elective perianal procedures
• ASA physical status I or II</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Known allergy to local anesthetics
Chronic opioid or analgesic use
Previous perianal surgery
Coagulopathy
Local infection at the site of infiltration</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K60</hc_code>
      <hc_code>K64.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fissure and fistula of anal and rectal regions</hc_keyword>
      <hc_keyword>Third degree hemorrhoids</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: International Non-proprietary Name (INN):Ropivacaine                                         Dose: 20 mL of 0.25% ropivacaine infiltration administered once at the end of surgery                              Duration of Treatment: Single intraoperative administration with postoperative assessment over 24hr                                                                                                                                                                   Mode of Delivery: Local surgical site infiltration (perianal wound infiltration)</i_keyword>
      <i_keyword>Control group: International Non-proprietary Name (INN):Normal Saline                                              Dose: 20 mL of 0.9% Normal Saline infiltration administered once at the end of surgery                  Duration of Treatment: Single intraoperative administration with postoperative assessment over 24hr                 Mode of Delivery: Local surgical site infiltration (perianal wound infiltration)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Post-operative Pain. Timepoint: It will be assessed at 6, 12 and 24 hours post-operatively. Method of measurement: Visual Analog Score for Pain 0-3 Mild 4-7 Moderate 8-10 Severe.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Requirement of Post-operative analgesic requirements. Timepoint: 24hours post-operatively. Method of measurement: Milligrams of analgesics used in both the groups.</sec_outcome>
      <sec_outcome>Time to first rescue analgesia. Timepoint: 24 hours post-operatively. Method of measurement: Hours post-operatively when analgesia was asked.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Fatima Memorial Hospital Lahore</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-04</approval_date>
        <contact_name>Institutional Review Board</contact_name>
        <contact_address>Shadman-1 Lahore Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
